EADV 2025: Interim Real-World Data from ADlife on Lebrikizumab in Moderate-to-Severe AD
New interim real-world data from the ADlife study explore the effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis. Early results at weeks 4 and 16 suggest promising clinical outcomes in a comorbid, treatment-experienced population.
Image courtesy of the European Academy of Dermatology and Venereology (EADV).
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen